

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

### Amendments to the Claims

This listing of the claims replaces all prior versions and listing of claims in the application.

1. (currently amended) A peptide compound of the formula [I] [SEQ. ID. NO. 4]:

Xaa<sub>1</sub> Xaa<sub>2</sub> Xaa<sub>3</sub> Xaa<sub>4</sub> Xaa<sub>5</sub> Xaa<sub>6</sub> Xaa<sub>7</sub> Xaa<sub>8</sub> Xaa<sub>9</sub> Xaa<sub>10</sub>  
Xaa<sub>11</sub> Xaa<sub>12</sub> Xaa<sub>13</sub> Xaa<sub>14</sub> Xaa<sub>15</sub> Xaa<sub>16</sub> Xaa<sub>17</sub> Ala Xaa<sub>19</sub> Xaa<sub>20</sub>  
Xaa<sub>21</sub> Xaa<sub>22</sub> Xaa<sub>23</sub> Xaa<sub>24</sub> Xaa<sub>25</sub> Xaa<sub>26</sub> Xaa<sub>27</sub> Xaa<sub>28</sub>-Z<sub>1</sub>; wherein

Xaa<sub>1</sub> is His, Arg, Tyr, Ala, Norval, Val or Norleu;

Xaa<sub>2</sub> is Ser, Gly, Ala or Thr;

Xaa<sub>3</sub> is Ala, Asp or Glu;

Xaa<sub>4</sub> is Ala, Norval, Val, Norleu or Gly;

Xaa<sub>5</sub> is Ala or Thr;

Xaa<sub>6</sub> is Ala, Phe, Tyr or naphthylalanine;

Xaa<sub>7</sub> is Thr or Ser;

Xaa<sub>8</sub> is Ala, Ser or Thr;

Xaa<sub>9</sub> is Ala, Norval, Val, Norleu, Asp or Glu;

Xaa<sub>10</sub> is Ala, Leu, Ile, Val, pentylglycine or Met;

Xaa<sub>11</sub> is Ala or Ser;

Xaa<sub>12</sub> is Ala or Lys;

Xaa<sub>13</sub> is Ala or Gln;

Xaa<sub>14</sub> is Ala, Leu, Ile, pentylglycine, Val or Met;

Xaa<sub>15</sub> is Ala or Glu;

Xaa<sub>16</sub> is Ala or Glu;

Xaa<sub>17</sub> is Ala or Glu;

Xaa<sub>19</sub> is Ala or Val;

Xaa<sub>20</sub> is Ala or Arg;

Xaa<sub>21</sub> is Ala or Leu;

09/554,531,  
Response Under 37 CFR 1.111

Patent  
238/087US

Xaa<sub>22</sub> is Phe, Tyr or naphthylalanine;  
Xaa<sub>23</sub> is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;  
Xaa<sub>24</sub> is Ala, Glu or Asp;  
Xaa<sub>25</sub> is Ala, Trp, Phe, Tyr or naphthylalanine;  
Xaa<sub>26</sub> is Ala or Leu;  
Xaa<sub>27</sub> is Ala or Lys;  
Xaa<sub>28</sub> is Ala or Asn;  
Z<sub>1</sub> is -OH,  
-NH<sub>2</sub>,  
Gly-Z<sub>2</sub>,  
Gly Gly-Z<sub>2</sub>  
Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub>-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub> Xaa<sub>38</sub>-Z<sub>2</sub> or  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub> Xaa<sub>38</sub> Xaa<sub>39</sub>-Z<sub>2</sub>;

wherein

Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine and N-alkylalanine; and

Xaa<sub>39</sub> is Ser or Tyr; and

Z<sub>2</sub> is -OH or -NH<sub>2</sub>;

provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>4</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>8</sub>, Xaa<sub>9</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, Xaa<sub>27</sub> and Xaa<sub>28</sub> are Ala; and provided also that, if Xaa<sub>1</sub> is His, Arg or Tyr, then at least one of Xaa<sub>3</sub>, Xaa<sub>4</sub> and Xaa<sub>9</sub> is Ala; and pharmaceutically acceptable salts thereof[;].

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

2. (currently amended) ☐ The compound according to claim 1 wherein Xaa<sub>1</sub> is His, Ala or Norval.

3. (currently amended) ☐ The compound according to claim 1 wherein Xaa<sub>1</sub> is Ala.

4. (currently amended) ☐ The compound according to claim 2 wherein Xaa<sub>1</sub> is Ala.

5. (currently amended) ☐ The compound according to claim 1 wherein Xaa<sub>1</sub> is His.

6. (currently amended) ☐ The compound according to claim 2 wherein Xaa<sub>1</sub> is His.

7. (currently amended) ☐ The compound according to claim 1 wherein Xaa<sub>2</sub> is Gly.

8. (currently amended) ☐ The compound according to claim 2 wherein Xaa<sub>2</sub> is Gly.

9. (currently amended) ☐ The compound according to claim 1 wherein Xaa<sub>3</sub> is Ala.

10. (currently amended) ☐ The compound according to claim 2 where Xaa<sub>3</sub> is Ala.

11. (currently amended) ☐ The compound according to claim 1 wherein Xaa<sub>4</sub> is Ala.

12. (currently amended) ☐ The compound according to claim 2 where Xaa<sub>4</sub> is

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

Ala.

13. (currently amended) [[A]] The compound according to claim 1 wherein Xaa<sub>9</sub> is Ala.

14. (currently amended) [[A]] The compound according to claim 2 where Xaa<sub>9</sub> is Ala.

15. (currently amended) [[A]] The compound according to any of claims 8-14 wherein Xaa<sub>14</sub> is Leu, pentylglycine or Met.

16. (currently amended) [[A]] The compound according to claim 15 wherein Xaa<sub>25</sub> is Trp or Phe.

17. (currently amended) [[A]] The compound according to claim 16 wherein Xaa<sub>6</sub> is Ala, Phe or naphthylalanine; Xaa<sub>22</sub> is Phe or naphthylalanine; and Xaa<sub>23</sub> is Ile or Val.

18. (currently amended) [[A]] The compound according to claim 17 wherein Z<sub>1</sub> is -NH<sub>2</sub>.

19. (currently amended) [[A]] The compound according to claim 17 wherein Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine.

20. (currently amended) [[A]] The compound according to claim 1 wherein Xaa<sub>39</sub> is Ser or Tyr.

21. (currently amended) [[A]] The compound according to claim 17 wherein Xaa<sub>39</sub> is Ser or Tyr.

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

22. (currently amended) [[A]] The compound according to claim 1 wherein Xaa<sub>39</sub> is Ser.

23. (currently amended) [[A]] The compound according to claim 17 wherein Xaa<sub>39</sub> is Ser.

24. (currently amended) [[A]] The compound according to claim 1 wherein Z<sub>2</sub> is -NH<sub>2</sub>.

25. (currently amended) [[A]] The compound according to any of claims 19, 21 or 23 wherein Z<sub>2</sub> is -NH<sub>2</sub>.

26. (currently amended) [[A]] The compound according to claim 1 wherein Z<sub>1</sub> is -NH<sub>2</sub>.

27. (currently amended) [[A]] The compound according to claim 1 wherein Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine.

28. (currently amended) [[A]] The compound according to claim 1 which has an amino acid sequence selected from SEQ. ID. NOS. 5 to 93.

29. (currently amended) A peptide compound of the formula [I] [SEQ. ID. NO. 4]:

Xaa<sub>1</sub> Xaa<sub>2</sub> Xaa<sub>3</sub> [[Xaa<sub>5</sub>]] Xaa<sub>4</sub> Xaa<sub>5</sub> Xaa<sub>6</sub> Xaa<sub>7</sub> Xaa<sub>8</sub> Xaa<sub>9</sub> Xaa<sub>10</sub> Xaa<sub>11</sub> Xaa<sub>12</sub> Xaa<sub>13</sub> Xaa<sub>14</sub>  
Xaa<sub>15</sub> Xaa<sub>16</sub> Xaa<sub>17</sub> Ala [[Xaa<sub>18</sub>]] Xaa<sub>19</sub> Xaa<sub>20</sub> Xaa<sub>21</sub> Xaa<sub>22</sub> Xaa<sub>23</sub> Xaa<sub>24</sub> Xaa<sub>25</sub> Xaa<sub>26</sub> Xaa<sub>27</sub>  
Xaa<sub>28</sub>-Z<sub>1</sub>; wherein

Xaa<sub>1</sub> is His or Ala;

Xaa<sub>2</sub> is Gly or Ala;

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

Xaa<sub>3</sub> is Ala, Asp or Glu;  
Xaa<sub>4</sub> is Ala or Gly;  
Xaa<sub>5</sub> is Ala or Thr;  
Xaa<sub>6</sub> is Ala, Phe or naphthylalanine;  
Xaa<sub>7</sub> is Thr or Ser;  
Xaa<sub>8</sub> is Ala, Ser or Thr;  
Xaa<sub>9</sub> is Ala, Asp or Glu;  
Xaa<sub>10</sub> is Ala, Leu or pentylglycine;  
Xaa<sub>11</sub> is Ala or Ser;  
Xaa<sub>12</sub> is Ala or Lys;  
Xaa<sub>13</sub> is Ala or Gln;  
Xaa<sub>14</sub> is Ala, Leu, Met or pentylglycine;  
Xaa<sub>15</sub> is Ala or Glu;  
Xaa<sub>16</sub> is Ala or Glu;  
Xaa<sub>17</sub> is Ala or Glu;  
Xaa<sub>19</sub> is Ala or Val;  
Xaa<sub>20</sub> is Ala or Arg;  
Xaa<sub>21</sub> is Ala or Leu;  
Xaa<sub>22</sub> is Phe or naphthylalanine;  
Xaa<sub>23</sub> is Ile, Val or tert-butylglycine;  
Xaa<sub>24</sub> is Ala, Glu or Asp;  
Xaa<sub>25</sub> is Ala, Trp or Phe;  
Xaa<sub>26</sub> is Ala or Leu;  
Xaa<sub>27</sub> is Ala or Lys;  
Xaa<sub>28</sub> is Ala or Asn;  
Z<sub>1</sub> is -OH,  
-NH<sub>2</sub>,  
Gly-Z<sub>2</sub>,  
Gly Gly-Z<sub>2</sub>  
Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser-Z<sub>2</sub>,

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

Gly Gly Xaa<sub>31</sub> Ser Ser-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>,  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub>-Z<sub>2</sub>  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub> Xaa<sub>38</sub>-Z<sub>2</sub>  
Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub> Xaa<sub>38</sub>  
Ser-Z<sub>2</sub>;

Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently Pro, homoproline, thioproline, or N-methylalanine; and

Z<sub>2</sub> is -OH or -NH<sub>2</sub>;

provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>8</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, Xaa<sub>27</sub>, and Xaa<sub>28</sub> are Ala; and provided that, if Xaa<sub>1</sub> is His, ~~Arg or Tyr~~, then at least one of Xaa<sub>3</sub>, Xaa<sub>4</sub> and Xaa<sub>9</sub> is Ala; and pharmaceutically acceptable salts thereof[.].

30. (currently amended) [[A]] The compound according to claim 29 which has an amino acid sequence selected from SEQ. ID. NOS. 5-9.

31. (currently amended) A composition comprising a compound of any one of claims 1 to 14, 16 to 24, and 26 to 29 in a pharmaceutically acceptable carrier.

32. (original) A composition comprising a compound of claim 30 in a pharmaceutically acceptable carrier.

33. (currently amended) A method for the treatment of diabetes mellitus comprising ~~the administration of~~ administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

34. (currently amended) A method for the treatment of diabetes mellitus comprising ~~the administration of~~ administering to a patient in need thereof a

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

therapeutically effective amount of a compound according to claim 28.

35. (currently amended) A method for the treatment of diabetes mellitus comprising ~~the administration of~~ administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 29.

36. (currently amended) The method of claim 33 further comprising the ~~administration of~~ administering a therapeutically effective amount of an insulin.

37. (currently amended) The method of claim 34 further comprising the ~~administration of~~ administering a therapeutically effective amount of an insulin.

38. (currently amended) The method of claim 35 further comprising the ~~administration of~~ administering a therapeutically effective amount of an insulin.

39. (currently amended) A method for the treatment of a hyperglycemic condition in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a compound according to claim 1.

40. (currently amended) A method for the treatment of a hyperglycemic condition in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a compound according to claim 28.

41. (currently amended) A method for the treatment of a ~~hypoglycemic~~ hyperglycemic condition in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a compound according to claim 29.

42. (currently amended) A peptide compound of the formula (II) [SEQ. ID. NO. 94]:





09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

Xaa<sub>1</sub>, Xaa<sub>2</sub>, Xaa<sub>3</sub>, Xaa<sub>4</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>7</sub>, Ala, Xaa<sub>9</sub>, Xaa<sub>20</sub>  
Xaa<sub>21</sub>, Xaa<sub>22</sub>, Xaa<sub>23</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, X<sub>1</sub>-Z<sub>1</sub>; wherein

Xaa<sub>1</sub> is His, Arg, Tyr, Ala, Norval, Val, Norleu or 4-imidazopropionyl;

Xaa<sub>2</sub> is Ser, Gly, Ala or Thr;

Xaa<sub>3</sub> is Ala, Asp or Glu;

Xaa<sub>4</sub> is Ala, Norval, Val, Norleu or Gly;

Xaa<sub>5</sub> is Ala or Thr;

Xaa<sub>6</sub> is Ala, Phe, Tyr or naphthylalanine;

Xaa<sub>7</sub> is Thr or Ser;

Xaa<sub>8</sub> is Ala, Ser or Thr;

Xaa<sub>9</sub> is Ala, Norval, Val, Norleu, Asp or Glu;

Xaa<sub>10</sub> is Ala, Leu, Ile, Val, pentylglycine or Met;

Xaa<sub>11</sub> is Ala or Ser;

Xaa<sub>12</sub> is Ala or Lys;

Xaa<sub>13</sub> is Ala or Gln;

Xaa<sub>14</sub> is Ala, Leu, Ile, pentylglycine, Val or Met;

Xaa<sub>15</sub> is Ala or Glu;

Xaa<sub>16</sub> is Ala or Glu;

Xaa<sub>17</sub> is Ala or Glu;

Xaa<sub>19</sub> is Ala or Val;

Xaa<sub>20</sub> is Ala or Arg;

Xaa<sub>21</sub> is Ala, Leu or Lys-NH<sup>ε</sup>-R where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl or cycloalkyl alkanoyl ~~Ala, Leu~~ or;

Xaa<sub>22</sub> is Phe, Tyr or naphthylalanine;

Xaa<sub>23</sub> is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;

Xaa<sub>24</sub> is Ala, Glu or Asp;

Xaa<sub>25</sub> is Ala, Trp, Phe, Tyr or naphthylalanine;

Xaa<sub>26</sub> is Ala or Leu;

X<sub>1</sub> is Lys Asn, Asn Lys, Lys-NH<sup>ε</sup>-R Asn, Asn Lys-NH<sup>ε</sup>-R, Lys-NH<sup>ε</sup>-R Ala, Ala Lys-NH<sup>ε</sup>-R where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl or

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

cycloalkylalkanoyl

Z<sub>1</sub> is -OH,

-NH<sub>2</sub>,

Gly-Z<sub>2</sub>,

Gly Gly-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub>-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub> Xaa<sub>38</sub>-Z<sub>2</sub> or

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub> Xaa<sub>38</sub> Xaa<sub>39</sub>-Z<sub>2</sub>;

wherein

Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine and N-alkylalanine; and

Xaa<sub>39</sub> is Ser or Tyr; and

Z<sub>2</sub> is -OH or -NH<sub>2</sub>.

provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>4</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>8</sub>, Xaa<sub>9</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, are Ala; and provided also that, if Xaa<sub>1</sub> is His, Arg, Tyr, or 4-imidazopropionyl then at least one of Xaa<sub>3</sub>, Xaa<sub>4</sub> and Xaa<sub>9</sub> is Ala; and pharmaceutically acceptable salts thereof.

43. (currently amended) [[A]] The compound according to claim 42 wherein Xaa<sub>1</sub> is His, Ala, Norval or 4-imidazopropionyl.

44. (currently amended) [[A]] The compound according to claim 43 wherein Xaa<sub>1</sub> is His or 4-imidazopropionyl.

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

45. (currently amended) ☐ The compound according to claim 43 wherein Xaa<sub>1</sub> is Ala.

46. (currently amended) ☐ The compound according to claim 43 wherein Xaa<sub>1</sub> is His.

47. (currently amended) ☐ The compound according to claim 43 wherein Xaa<sub>1</sub> is 4-imidazopropionyl.

48. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>2</sub> is Gly.

49. (currently amended) ☐ The compound according to any of claims 43-47 wherein Xaa<sub>2</sub> is Gly.

50. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>3</sub> is Ala.

51. (currently amended) ☐ The compound according to any of claims 43-47 where Xaa<sub>3</sub> is Ala.

52. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>4</sub> is Ala.

53. (currently amended) ☐ The compound according to any of claims 43-47 where Xaa<sub>4</sub> is Ala.

54. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>9</sub> is Ala.

55. (currently amended) ☐ The compound according to any of claim 43-47

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

where Xaa<sub>9</sub> is Ala.

56. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>14</sub> is Leu, pentylglycine or Met.

57. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>25</sub> is Trp or Phe.

58. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>6</sub> is Ala, Phe or naphthylalanine; Xaa<sub>22</sub> is Phe or naphthylalanine; and Xaa<sub>23</sub> is Ile or Val.

59. (currently amended) ☐ The compound according to claim 42 wherein Z<sub>1</sub> is -NH<sub>2</sub>.

60. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine.

61. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>39</sub> is Ser or Tyr.

62. (currently amended) ☐ The compound according to claim 58 wherein Xaa<sub>39</sub> is Ser or Tyr.

63. (currently amended) ☐ The compound according to claim 42 wherein Xaa<sub>39</sub> is Ser.

64. (currently amended) ☐ The compound according to claim 58 wherein Xaa<sub>39</sub> is Ser.

09/554,531  
Response Under 37 CFR 1.111

Patent  
238/087US

65. (currently amended) [[A]] The compound according to claim 42 wherein Z<sub>2</sub> is -NH<sub>2</sub>.

66. (currently amended) [[A]] The compound according to any of claims 50, 52 or 54 wherein Z<sub>2</sub> is -NH<sub>2</sub>.

67. (currently amended) [[A]] The compound according to claim 42 wherein Z<sub>1</sub> is [[ -NH<sub>2</sub> ]] -OH.

68. (currently amended) [[A]] The compound according to claim 42 wherein Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine.

69. (currently amended) [[A]] The compound according to claim 42 wherein X<sub>1</sub> is Lys Asn, Lys-NH<sup>e</sup>-R Asn, or Lys-NH<sup>e</sup>-R Ala where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl.

70. (currently amended) [[A]] The compound according to claim 42 wherein Xaa<sub>21</sub> is Lys-NH<sup>e</sup>-R where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl or cycloalkyl-alkanoyl.

71. (currently amended) [[A]] The compound according to claim 42 which has an amino acid sequence selected from SEQ. ID. NOS. 95-110.

72. (original) A composition comprising a compound of claim 42 in a pharmaceutically acceptable carrier.

73. (original) A composition comprising a compound of claim 71 in a pharmaceutically acceptable carrier.